Return to homepagePandemic Pact

Development and Evaluation of SARS- CoV-2 RNA Polymerase Inhibitors

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:2 publications

Grant number: 170343

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $502,766.41

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    Matthias Götte

  • Research Location

    Canada

  • Lead Research Institution

    University of Alberta

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2011, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we oppose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.

Publicationslinked via Europe PMC

Last Updated:2 days ago

View all publications at Europe PMC

Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo Hemorrhagic Fever Virus full-length L-protein.

Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.